全球糖尿病患者迅速增加 80%分布于中低收入

  • 糖尿病,5.92亿人
  • 中国新闻网

据新加坡《联合早报》3日报道,糖尿病患者数量正在全球迅速增加。据国际糖尿病联合会统计,2013年全球糖尿病患者数量达3.82亿人,较2003年时的1.94亿翻了一番。预计到2035年,这一数字将达到5.92亿人。

伴随经济的增长,印度和非洲的糖尿病发病状况也在逐年恶化。据统计,糖尿病患者中,约80%分布在中低收入国家。2013年糖尿病人口排名中,中国、印度、美国位列前三。2013年,全球约510万人死于糖尿病,数量接近因吸烟而死亡者(600万人)。

世界卫生组织在2013至2020年行动计划中提出,争取到2025年使糖尿病等非传染性疾病死亡人数减少25%。

联合国粮食权问题特别报告员德许特今年5月警告称,高热量和营养失衡的垃圾食品等不健康食品“相比烟草对健康的威胁更大”,呼吁各国尽快采取限制措施。

This link:http://www.chemcd.com/news/3715.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.